Liminal BioSciences Inc. PFSCF

RE:RE:Canaccord Genuity: Buy rating and $4.25 target price for PLI

[Atomek]

House Positions for C:PLI from 20151111 to 20151111

House	Bought	$Val	Ave	Sold	$Val	Ave	Net	$Net
33 Canaccord	100,400	263,710	2.627	8,500	22,135	2.604	91,900	-241,575
2 RBC	137,583	360,080	2.617	111,371	291,566	2.618	26,212	-68,514
79 CIBC	67,070	175,445	2.616	45,184	118,451	2.622	21,886	-56,994
85 Scotia	123,574	323,014	2.614	105,060	276,237	2.629	18,514	-46,777
19 Desjardins	71,341	186,702	2.617	57,752	150,868	2.612	13,589	-35,834
56 Edward Jones	5,500	14,409	2.62	0			5,500	-14,409
53 Morgan Stanley	5,100	13,330	2.614	0			5,100	-13,330
57 Interactive	1,150	2,991	2.601	0			1,150	-2,991
88 Credential	690	1,807	2.619	0			690	-1,807
28 BBS	600	1,578	2.63	0			600	-1,578
76 Industrial Alliance	327	850	2.599	0			327	-850
48 Laurentian	4,000	10,640	2.66	4,000	10,480	2.62	0	-160
16 Paradigm	50,000	131,500	2.63	50,000	130,627	2.613	0	-873
22 Fidelity	1,000	2,630	2.63	1,095	2,868	2.619	-95	238
101 SG Capital	4,100	10,678	2.604	4,400	11,606	2.638	-300	928
99 Jitney	26,200	68,705	2.622	26,800	70,328	2.624	-600	1,623
124 Questrade	6,085	15,744	2.587	7,400	19,314	2.61	-1,315	3,570
59 PI	0			1,500	3,960	2.64	-1,500	3,960
14 ITG	11,400	30,210	2.65	15,750	41,087	2.609	-4,350	10,877
39 Merrill Lynch	72,700	189,604	2.608	77,600	203,226	2.619	-4,900	13,622
13 Instinet	33,500	87,825	2.622	39,700	104,423	2.63	-6,200	16,598
7 TD Sec	233,701	612,032	2.619	246,253	646,083	2.624	-12,552	34,051
9 BMO Nesbitt	25,579	67,293	2.631	46,770	122,505	2.619	-21,191	55,212
90 Barclays	0			26,700	70,264	2.632	-26,700	70,264
80 National Bank	59,425	155,800	2.622	101,665	267,502	2.631	-42,240	111,702
1 Anonymous	289,900	760,429	2.623	353,425	923,476	2.613	-63,525	163,047
TOTAL	1,330,925	3,487,006	2.62	1,330,925	3,487,006	2.62	0	0

From orphan drug to potential blockbuster
Investment Recommendation
New indication transforms our view of ProMetic’s lead drug plasminogen. ProMetic has acquired the commercial rights to plasminogen in diabetic wound-healing from Omnio AB. Recall that plasminogen is ProMetic’s most advanced plasma-derived therapeutic currently in a short, low-risk 20-patient clinical trial for plasminogen-deficiency with data expected in the middle of next year. Even without this new indication, plasminogen was a key value driver in our model, with total peak revenues currently forecast to be in excess of $200 million. Now, with a potential market of millions, we believe that plasminogen has blockbuster potential, with a market size that will be limited only by ProMetic’s ability to manufacture the drug.
ProMetic remains one of our Focus List picks, as we anticipate a transformational 2016 for the company. Given the substantial news flow expected over the next few months, we would continue to be aggressive buyers of the stock at these levels.

They are putting money where their mouth is .
A